Heart Failure

Savarese G, Lund LH. Global public health burden of heart failure. Cardiac failure review. 2017;3(1):7.

Szekanecz Z, McInnes IB, Schett G, Szamosi S, Benkő S, Szűcs G. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nature Reviews Rheumatology. 2021;17(10):585-95.

Sarzi-Puttini P, Atzeni F, Gerli R, Bartoloni E, Doria A, Barskova T, et al. Cardiac involvement in systemic rheumatic diseases: an update. Autoimmunity reviews. 2010;9(12):849-52.

Baoqi Y, Dan M, Xingxing Z, Xueqing Z, Yajing W, Ke X, Liyun Z. Effect of anti-rheumatic drugs on cardiovascular disease events in rheumatoid arthritis. Frontiers in Cardiovascular Medicine. 2022;8:812631.

Schwinger RH. Pathophysiology of heart failure. Cardiovascular diagnosis and therapy. 2021;11(1):263.

Snipelisky D, Chaudhry S-P, Stewart GC. The many faces of heart failure. Cardiac electrophysiology clinics. 2019;11(1):11-20.

Varghese TP, Tazneem B. Unraveling the complex pathophysiology of heart failure: insights into the role of renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS). Current Problems in Cardiology. 2024;49(4):102411.

Marti CN, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, Quyyumi AA, Butler J. Endothelial dysfunction, arterial stiffness, and heart failure. Journal of the American College of Cardiology. 2012;60(16):1455-69.

Luo M, Anderson ME. Mechanisms of altered Ca2+ handling in heart failure. Circulation research. 2013;113(6):690-708.

Lam CS, Solomon SD. Classification of heart failure according to ejection fraction: JACC review topic of the week. Journal of the American College of Cardiology. 2021;77(25):3217-25.

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American college of cardiology. 2013;62(16):e147-e239.

Bennett JA, Riegel B, Bittner V, Nichols J. Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart Lung. 2002;31(4):262-70.

Løgstrup BB. Heart Failure in Rheumatic Disease: Secular Trends and Novel Insights. Rheum Dis Clin North Am. 2023;49(1):67-79.

Ahlers MJ, Lowery BD, Farber‐Eger E, Wang TJ, Bradham W, Ormseth MJ, et al. Heart failure risk associated with rheumatoid arthritis–related chronic inflammation. Journal of the American Heart Association. 2020;9(10):e014661.

Torralba KD, Rolle NA, Sandhu VK. Cardiovascular disease in systemic lupus erythematosus and antiphospholipid antibody syndrome. Interdisciplinary Rheumatology: CRC Press; 2024. p. 61-71.

Castaneda S, Gonzalez-Juanatey C, Gonzalez-Gay MA. Inflammatory arthritis and heart disease. Current pharmaceutical design. 2018;24(3):262-80.

Papagoras C, Voulgari PV, Drosos AA. Cardiovascular disease in spondyloarthritides. Current vascular pharmacology. 2020;18(5):473-87.

Parperis K, Constantinou A. Calcium pyrophosphate crystal deposition: insights to risks factors and associated conditions. Current Rheumatology Reports. 2024;26(11):375-82.

Sezen Y, Buyukatipoglu H, Kucukdurmaz Z, Geyik R. Cardiovascular involvement in Behçet’s disease. Clinical rheumatology. 2010;29:7-12.

Lambova S. Cardiac manifestations in systemic sclerosis. World journal of cardiology. 2014;6(9):993.

Gori T. Coronary vasculitis. Biomedicines. 2021;9(6):622.

Cabassi A, Tedeschi S, Perlini S, Verzicco I, Volpi R, Gonzi G, Canale SD. Non-steroidal anti-inflammatory drug effects on renal and cardiovascular function: from physiology to clinical practice. European journal of preventive cardiology. 2020;27(8):850-67.

Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert opinion on drug safety. 2016;15(4):457-65.

Deftereos SG, Beerkens FJ, Shah B, Giannopoulos G, Vrachatis DA, Giotaki SG, et al. Colchicine in cardiovascular disease: in-depth review. Circulation. 2022;145(1):61-78.

Urschel K, Cicha I. TNF-α in the cardiovascular system: from physiology to therapy. International Journal of Interferon, Cytokine and Mediator Research. 2015:9-25.

Marks JL, Edwards CJ. Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity. Therapeutic advances in musculoskeletal disease. 2012;4(3):149-57.

Tselios K, Gladman DD, Harvey P, Mak S, Chantal M, Butany J, Urowitz MB. Hydroxychloroquine-induced cardiomyopathy in systemic lupus erythematosus. JCR: Journal of Clinical Rheumatology. 2016;22(5):287-8.

Floris A, Piga M, Mangoni AA, Bortoluzzi A, Erre GL, Cauli A. Protective effects of hydroxychloroquine against accelerated atherosclerosis in systemic lupus erythematosus. Mediators of inflammation. 2018;2018(1):3424136.

Qavi AH, Kamal R, Schrier RW. Clinical use of diuretics in heart failure, cirrhosis, and nephrotic syndrome. International journal of nephrology. 2015;2015(1):975934.

Parthasarathy P, Vivekanandan S. Urate crystal deposition, prevention and various diagnosis techniques of GOUT arthritis disease: a comprehensive review. Health information science and systems. 2018;6:1-13.

Wolff ML, Cruz JL, Vanderman AJ, Brown JN. The effect of angiotensin II receptor blockers on hyperuricemia. Therapeutic Advances in Chronic Disease. 2015;6(6):339-46.

Ruilope LM, Rosei EA, Bakris GL, Mancia G, Poulter NR, Taddei S, et al. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood pressure. 2005;14(4):196-209.

Wigley FM, Herrick AL. Management of Raynaud’s phenomenon and digital ulcers. Current Treatment Options in Rheumatology. 2015;1:68-81.

Lam CS, Chandramouli C, Ahooja V, Verma S. SGLT‐2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects. Journal of the American Heart Association. 2019;8(20):e013389.

Tatu AL, Elisei AM, Chioncel V, Miulescu M, Nwabudike LC. Immunologic adverse reactions of β-blockers and the skin. Experimental and therapeutic medicine. 2019;18(2):955-9.